Literature DB >> 6449312

Selective uptake and retention of anticancer agents by sensitive cells.

D L Hill, J A Montgomery.   

Abstract

Considerable evidence has been accumulated to demonstrate that sensitive tumor cells in experimental animals take up and retain at least some effective anticancer drugs to a greater extent than normal tissues, thus providing a greater degree of exposure and accounting for the selective effect of the drugs. In sensitive cells, DNA synthesis is inhibited for prolonged periods, whereas in cells less sensitive the time of inhibition is shorter. In those cases examined where a metabolite, formed intracellularly, is the active form of the agent, the metabolite is produced and is retained to a greater extent than in normal tissues.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6449312     DOI: 10.1007/bf00255265

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.

Authors:  F M Sirotnak; R C Donsback
Journal:  Cancer Res       Date:  1975-07       Impact factor: 12.701

2.  Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.

Authors:  F M Sirotnak; R C Donsbach; D M Dorick; D M Moccio
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

3.  Metabolism and intracellular retention of 1-beta-D-arabinofuranosylcytosine as predictors of response of animal tumors.

Authors:  Y M Rustum
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

4.  Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells.

Authors:  P L Chello; F M Sirotnak; D M Dorick; R C Donsbach
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

5.  Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.

Authors:  F M Sirotnak; R C Donsbach
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

6.  Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy.

Authors:  J G Mayo; W R Laster; C M Andrews; F M Schabel
Journal:  Cancer Chemother Rep       Date:  1972-04

7.  Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell.

Authors:  I D Goldman; N S Lichtenstein; V T Oliverio
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

8.  Factors determining cell killing by chemotherapeutic agents in vivo. I. Cyclophosphamide.

Authors:  L M van Putten; P Lelieveld
Journal:  Eur J Cancer       Date:  1970-08       Impact factor: 9.162

9.  Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.

Authors:  Y M Rustum; H D Preisler
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

Review 10.  Proliferation-dependent cytotoxicity of anticancer agents: a review.

Authors:  F Valeriote; L van Putten
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

View more
  2 in total

Review 1.  Is the P388 murine tumor no longer adequate as a drug discovery model?

Authors:  T H Corbett; F A Valeriote; L H Baker
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

Authors:  M J Yagi; M Zanjani; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.